Literature DB >> 1985825

Alterations in the renal excretion of valproate and its metabolites after chronic treatment.

J E Fisher1, H Nau, W Löscher.   

Abstract

Urinary excretion of valproate (VPA, administered as its sodium salt) and its various metabolites was studied in rats before and after 6 weeks of chronic treatment with intraperitoneal (i.p.) injection of 200 mg/kg VPA three times daily. Urinary excretion was determined after i.p. injection of a single dose of 200 mg/kg VPA, to which [14C]labeled VPA had been added to yield a dose of 1 microCi/kg body weight. Unlabeled VPA and metabolites were determined in urine by gas chromatography-mass spectrometry (GC-MS). After injection of a single dose of VPA before onset of chronic treatment, approximately 40-50% of the dose administered was excreted in the urine within 24 h, mainly in the form of conjugated VPA and omega-oxidation products, i.e., 5-hydroxy-VPA and 2-propyl-glutaric acid. After chronic treatment, urinary excretion of total radioactivity increased approximately 75% as compared with activity before chronic treatment, demonstrating a marked increase in elimination rate of VPA during prolonged administration. Determination of VPA and metabolites in urine by GC-MS indicated that this enhanced elimination resulted mainly from increases in glucuronidation and beta-oxidation of VPA, whereas omega-oxidation was apparently not altered or was even reduced. The data strongly indicate that at least in rats VPA produces induction of its own metabolism during prolonged treatment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1985825     DOI: 10.1111/j.1528-1157.1991.tb05627.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  4 in total

1.  Apparent autoinduction of valproate beta-oxidation in humans.

Authors:  D B McLaughlin; J A Andrews; W D Hooper; G R Cannell; M J Eadie; R G Dickinson
Journal:  Br J Clin Pharmacol       Date:  2000-05       Impact factor: 4.335

2.  Glucuronidation metabolic kinetics of valproate in guinea pigs: nonlinear at clinical concentration levels.

Authors:  H Y Yu; Y Z Shen
Journal:  Pharm Res       Date:  1996-08       Impact factor: 4.200

3.  Histone deacetylase inhibitors valproate and trichostatin A are toxic to neuroblastoma cells and modulate cytochrome P450 1A1, 1B1 and 3A4 expression in these cells.

Authors:  Jana Hřebačková; Jitka Poljaková; Tomáš Eckschlager; Jan Hraběta; Pavel Procházka; Svatopluk Smutný; Marie Stiborová
Journal:  Interdiscip Toxicol       Date:  2009-09-28

4.  Three patients needing high doses of valproic Acid to get therapeutic concentrations.

Authors:  James Jackson; Betsy McCollum; Judy Ognibene; Francisco J Diaz; Jose de Leon
Journal:  Case Rep Psychiatry       Date:  2015-04-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.